Neuphoria Therapeutics, Inc.

Contributing Author

Recent Articles by Neuphoria Therapeutics, Inc.

Sep-04	Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD) NEUP GlobeNewswire
Aug-28	Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference NEUP GlobeNewswire
May-27	Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting NEUP GlobeNewswire
May-20	Neuphoria Provides First Quarter 2025 Business Updates NEUP GlobeNewswire